Reframe Daily is where Christin Chong (neuroscience PhD, chaplain, healthtech strategy consultant) curates optimistic and credible healthtech news so you don’t have to.
Today in one sentence: A brand-new germ-killing medicine beat superbugs in mice, a two-day-a-week low-cal diet plus light weights slowed breast cancer, mindfulness meditation tamed gaming cravings and repaired brain wiring, a Thai probiotic lowered harmful blood toxins in kidney patients, and quick gene tests helped doctors pick anxiety pills with fewer side effects.
Christin’s note: found any of today’s news interesting and want to apply it to your life or help a loved one out? let’s talk about it in the reframe community!
Sign up here → https://forms.gle/tN3oabFTsDF21VnS8
Good news: Scientists created a brand-new antibiotic that kills many drug-resistant germs in mice and did not let them develop resistance.
Market readiness: 🙂🙂 (animal studies show promise but human trials haven’t started)
Good news: A small cancer trial found that combining an off-and-on “2-days-low-calorie” diet with light weight-training helped women on chemotherapy stay healthier and slowed their breast-cancer growth compared with exercise alone.
Market readiness: 🙂🙂🙂 (phase-2 human data; needs bigger trials before routine care)
Good news: Eight weeks of guided mindfulness meditation rewired brain networks and cut gaming cravings in people with internet-gaming disorder better than relaxation training.
Market readiness: 🙂🙂🙂🙂🙂 (meditation is already accessible—study shows clear clinical benefit)
Good news: A four-week study showed that a Thai strain of the probiotic Lacticaseibacillus rhamnosus lowered harmful uremic toxins and inflammation in people with chronic kidney disease who aren’t yet on dialysis.
Market readiness: 🙂🙂🙂🙂 (probiotic capsules exist, but larger trials are needed for CKD labeling)
Good news: Giving doctors each patient’s drug-metabolism genes before prescribing anxiety medicine reduced side-effects and cut hospital visits in the first head-to-head test of pre-emptive pharmacogenomics for anxiety disorders.
Market readiness: 🙂🙂🙂🙂 (clinical service is feasible now, but insurance coverage is limited)Thank you for taking the time to take care of yourself and your loved ones.
